🇺🇸 Liposomal paclitaxel in United States

14 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bone Marrow Failure — 3 reports (21.43%)
  2. Hepatic Function Abnormal — 3 reports (21.43%)
  3. Death — 1 report (7.14%)
  4. Diarrhoea — 1 report (7.14%)
  5. Fall — 1 report (7.14%)
  6. Femur Fracture — 1 report (7.14%)
  7. Full Blood Count Decreased — 1 report (7.14%)
  8. Hepatic Enzyme Increased — 1 report (7.14%)
  9. Pancreatitis — 1 report (7.14%)
  10. Renal Impairment — 1 report (7.14%)

Source database →

Liposomal paclitaxel in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Liposomal paclitaxel approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Liposomal paclitaxel in United States?

Beijing Tongren Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.